ArticleJournal of nanobiotechnology2025
Coronavesicle-engineered hydrogel sequential photothermal-immunometabolic therapy reprograms tissue microenvironment for diabetic-infected wounds healing.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- NIR-Assisted Multimodal Strategies for Enhanced Antibacterial Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Hydrogel-extracellular vesicle engineering delivery system: a promising therapeutic strategy for wound healing.Journal of nanobiotechnology · 2026Review
- Emerging nanotechnological strategies for delivering bioactive components from botanical drugs and traditional Chinese medicine in atherosclerosis therapy: from formulation to mechanism.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Persistent infection and dysregulated tissue microenvironment constitute the primary obstacles hindering the healing of infectious diabetic wounds. Herein, we developed an NIR-responsive hydrogel dressing incorporating polyphenol-engineered plant-derived nanovesicles (termed Coronavesicles) via an in-situ deposition strategy, designed to implement sequential photothermal-immunometabolic therapy for infectious diabetic wounds. The coronavesicles within the hydrogel preferentially adhere to bacterial surfaces to deliver localized photothermal therapy (PTT), wherein subsequent heat-triggered rupture releases intrinsic bioactive constituents to enhance antibacterial efficacy. Following bacterial clearance, the released components from coronavesicles synergistically modulate fibroblast proliferation, alleviate oxidative stress, and reverse macrophage-mediated inflammatory immunity. This multi-pronged therapeutic strategy demonstrates desirable treatment outcomes both in vitro and in vivo. This work contributes to the understanding and future development of engineering plant-derived nanovesicles for diabetic wound management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.